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Abstract. CCN is an acronym for cysteine-rich protein 61 
(CYR61), connective tissue growth factor (CTGF) and nephro-
blastoma overexpressed (NOV). Aberrations of certain CCN 
members including CYR61, CTGF, Wnt1-inducible signal-
ling pathway protein (WISP)-1 and -3 have been reported in 
gastric cancer. The present study aimed to examine the clinical 
relevance of NOV along with CYR61 and CTGF in gastric 
cancer by analysing their transcript levels. CYR61, CTGF and 
NOV transcript expression in 324 gastric cancer samples with 
paired adjacent normal gastric tissues were determined using 
real-time quantitative PCR and the results were statistically 
analysed against patient clinicopathological data using SPSS 
software. NOV mRNA levels in gastric cancer tissues were signiicantly elevated when compared with levels in their paired 
adjacent non-cancerous tissues. Local advanced tumours with 
invasive expansion (T3 and T4) expressed higher levels of NOV 
(p=0.013) compared with the less invasive tumours (T1 and T2). CYR61 transcript levels were also signiicantly increased 
in gastric cancers compared with levels in the adjacent non-
cancerous tissues. Kaplan-Meier survival curves revealed that 
patients with CYR61-low transcript levels had longer overall 
survival (OS) (p=0.018) and disease-free survival (DFS) 
(p=0.015). NOV overexpression promoted the in vitro prolifera-
tion of AGS cells while the knockdown resulted in a reduced 
proliferation of HGC27 cells. A similar effect was observed 
for the invasion of these two gastric cancer cell lines. NOV 
expression was increased in gastric cancer which was associated 
with local invasion and distant metastases. Taken together, the 
expression of NOV and CYR61 was increased in gastric cancer. 
The elevated expression of CYR61 was associated with poorer 
survival. NOV promoted proliferation and invasion of gastric 
cancer cells. Further investigations may highlight their predic-
tive and therapeutic potential in gastric cancer.
Introduction
Gastric cancer (GC) is the fourth most commonly diagnosed cancer in males and the ifth in females worldwide, with over 
751,600 new cases and 723,100 deaths estimated to have 
occurred in 2012 (1). The highest incidence rates are found 
in Eastern Asia (particularly in Korea, Mongolia, Japan and 
China), Central and Eastern Europe, and South America, and 
the lowest incidences are noted in Northern America and most 
parts of Africa. The incidence is twice higher in males than in 
females (1).
The tumor microenvironment plays a pivotal role in 
tumourigenesis and subsequent dissemination of cancer cells 
by coordinating morphological transformation of cancer cells 
and their proliferation, survival and invasion (2,3). Recent 
reviews have highlighted a profound role played by a group 
of proteins in the tumour microenvironment which belong 
to the CCN family. CCN is an acronym for cysteine-rich 
protein 61 (CYR61), connective tissue growth factor (CTGF) 
and nephroblastoma overexpressed (NOV) which comprises 
CYR61, CTGF, NOV and another three members i.e. Wnt1-
inducible signalling pathway protein (WISP)-1, -2 and -3 (4-6).
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CCNs are matricellular proteins and can be secreted 
into the extracellular matrix. CCN3 can be detected in the 
culture medium, extracellular matrix (ECM) and at the 
cell membrane (7-9). The CCN family proteins have been 
preserved during evolution which can be found in vertebrates including zebra ish, chickens, mice, rats and humans. CCN 
proteins generally have an N-terminal secretory signal peptide 
and four functional domains: an insulin-like growth factor 
binding protein domain (IGFBP); a Von Mayebrand factor 
type C (VWC) domain; a thrombospondin type-1 repeat 
module (TSP-1) and a cysteine knot domain (CT). The two 
N-terminal domains are separated from the two C-domains 
by a linker with a variable sequence of amino acids. However, 
CCN5 does not have the CT domain (10).
An elevated expression of CCN1 has been demonstrated 
in a variety of malignancies including ovarian, prostate, 
breast and colorectal cancers (11-14). Similarly, an overex-
pression of CTGF has been noted in breast and colorectal 
cancer, oesophageal squamous cell carcinoma and pancreatic 
cancer (15-18), while increased expression of NOV has been 
shown in prostate and cervical cancers (19,20). In contrast to these indings, reduced expression of these three CCNs has 
also been observed in certain solid tumours. For example, 
CYR61 expression is reduced in endometrial cancer and lung 
cancer (21,22). A reduced expression of CYR61 has also been 
seen in advanced GC (23). CTGF can act as an inhibitor in 
lung cancer by suppressing proliferation of non-small cell 
lung cancer cells (24). A similar inhibitory effect on the 
proliferation of cancer cells has also been evident for the NOV 
protein in gliobastoma and malignant adrenocortical tumour 
cells (25,26). This suggests that the expression and function of CCNs in malignancies can be organ- or tissue-speciic.
Early studies have demonstrated a profound role played by CCNs in ibrosis which has been reviewed most recently 
by Riser et al (6). Their involvement in fibrotic disorder 
stimulated research interest concerning their implication in a speciic histologic type of gastric carcinoma, i.e. scirrhous carcinoma which is well known for a vast ibrous stroma, rapid 
and invasive growth and poor prognosis. Tanaka et al identi-ied a novel variant of WISP1 that was highly expressed in 
scirrhous carcinomas. This variant lacks the von Mayebrand 
type C module and is named WISP1v. WISP1v can induce 
transformation and promote proliferation and invasion of GC 
cells through both autocrine and paracrine pathways (27). 
Tanaka et al also reported a loss of function mutation of WISP3 
with a frequency of 10-20% in microsatellite unstable gastric 
carcinoma. This mutation resulted in a truncated variant of 
WISP3 that was lacking the TSP-1 and CT domains and was 
unable to suppress the invasiveness of GC cells (28). Although 
reduced expression of CYR61 was reported in advanced 
GC which was inversely correlated with the expression of 
MMP-7 (23), most studies demonstrated a positive role played 
by CYR61 in GC by promoting invasion, metastasis and also 
tumour-associated angiogenesis (29,30). CYR61 promotes GC 
cell invasion through hypoxia-inducing factor-1α (HIF-1α)-
dependent upregulation of plasminogen activator inhibitor-1 
(PAI-1) (31).
Elevated expression of CYR61 and CTGF has been 
observed in GC which is associated with lymph node metas-
tasis, however the expression of NOV in GC is yet to be 
revealed. The present study aimed to determine the expression 
of these three CCNs in a cohort of GC tumours, in particular, 
by dissecting the role played by NOV in GC.
Materials and methods
Cell lines and culture conditions. Human GC cell lines AGS 
and HGC27 were purchased from the European Collection of Cell Cultures (ECACC; Salisbury, UK) and incubated at 37˚C, 
with 5% CO2 and 95% humidity. The wild-type cells were maintained in Dulbecco's modiied Eagle's medium (DMEM) 
supplemented with 10% fetal calf serum (PAA Laboratories 
Ltd., Somerset, UK), penicillin, streptomycin and ampho-
tericin B.
Human gastric tissues. Gastric adenocarcinoma and Siewert 
type III gastrooesophageal junction adenocarcinoma tissues 
(n=245) with matched adjacent background tissues (n=158) 
were immediately collected after surgical resection at the 
Beijing Cancer Hospital with informed consent from the 
patients. All patients underwent surgery without any prior treatment. The tissue samples were stored at -80˚C at the 
Tissue Bank of Peking University Oncology School with a 
record of the relevant clinical and histopathological data. All 
protocols were reviewed and approved by the Beijing Cancer 
Hospital Research Ethics Committee (MTA10062009).
RNA isolation, reverse transcription-polymerase chain reac-
tion (RT-PCR) and quantitative real-time PCR (qPCR). RNA was extracted from conluent cells in a 25 cm2 lask using 
total RNA isolation (TRI) reagent (Sigma-Aldrich, Dorset, UK). Fresh frozen tissues were also irst homogenised in the 
TRI reagent. First strand of cDNA was synthesised from 1 µg RNA using a irst-strand DNA synthesis kit (Bio-Rad, Hemel 
Hempstead, UK). Quantitative analysis of NOV mRNA expres-sion in GC tissues was performed using Ampliluor™-based 
real-time PCR, in which a 6-carboxy-fluorescine-tagged Uniprimer™ (Biosearch Technologies, Inc.) was used as a probe along with a pair of speciic primers with an addition 
of a Z-sequence (actgaacctgaccgtaca) to the 5'-end of the reverse primer. The quality of cDNA samples was veriied 
using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
as a housekeeping gene. All the primer sequences are listed 
in Table I.
Quantitative analyses of transcript expression of CYR61, 
CTGF and NOV in human GC. Following the real-time PCR quantiication of each gene transcripts, the number of samples 
with valid data for each individual genes were: 322 samples 
for NOV, 252 samples for CYR61 and 320 samples for CTGF. 
These cohorts were composed of 230 men (71.4%) and 
92 women (28.6%) in the NOV cohort, 180 men (71.4%) and 
72 women (28.6%) in the CYR61 cohort, and 228 men (71.3%) 
and 92 women (28.7%) in the CTGF cohort. Data are shown 
in Tables II-IV.
Construction of the ribozyme transgene targeting human NOV 
and the establishment of corresponding stable transfectants. 
Anti-human NOV hammerhead ribozymes were designed 
using the Zuker RNA mFold program (Zuker 2003). The ribo-
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zymes and full-length coding sequence of human NOV were 
cloned into a pEF6/V5-His TOPO vector (Invitrogen, Paisley, 
UK). The verified ribozyme transgenes, NOV expression 
vectors and empty plasmids were transfected into AGS and 
HGC27 cells, respectively, using an Easyjet Plus electroporator 
(EquiBio, Kent, UK). After one week of selection with 5 µg/ml 
blasticidin, the selected cells were maintained in DMEM with 
0.5 µg/ml blasticidin.
Western blot analysis. The protein concentrations in the cell 
lysates were determined using the DC protein assay kit (Bio-
Rad) and the ELx800 spectrophotometer (Bio-Tek, Winooski, 
VT, USA). Proteins were probed with the anti-NOV antibody 
(1:2,000; Abcam, Ltd., Cambridge, UK) and anti-GAPDH 
antibody (1:2,000; Santa Cruz Biotechnology, Inc.) as house-
keeping gene control, followed by a peroxidase-conjugated 
secondary antibody (1:2,000; Sigma). Protein bands were visu-
alised using a chemiluminescence detection kit (Luminata, 
Millipore Ltd., Watford, UK) and photographed using Syngene 
imager (Syngene International Ltd., Bangalore, India).
In vitro cell growth assay. Cells (3,000) were seeded into 
96-well plates in normal culture medium. The cells were incubated over a period of up to 4 days, and were then ixed 
with 4% formaldehyde followed by staining with 0.5% crystal 
violet. The crystal violet was dissolved in 10% acetic acid prior 
to a colorimetric detection of cell density at a wavelength of 
540 nm using the ELx800 spectrophotometer.
In vitro invasion assay. The in vitro invasion assay was 
previously described (32). All the culture plate inserts 
containing 8-µm pores were pre-coated with 50 µg of Matrigel 
(BD Bioscience, Oxford, UK) and air-dried. Cells (30,000) 
were seeded to each well after a 40-min rehydration of the 
Matrigel. After an incubation of 72 h, cells that had migrated through the matrix to the other side of the insert were ixed 
and stained. The cell number was determined.
Cell-matrix adhesion assay. The cell-matrix adhesion assay 
was conducted as previously described (32). The 96-well 
culture plate was pre-coated with 5 µg of Matrigel and 
air-dried. Following the rehydration, 30,000 cells were seeded 
to each well. After an incubation of 40 min, non-adherent cells 
were washed-off using phosphate-buffered saline (PBS). The adherent cells were counted after a ixation and staining using 
crystal violet.
Wound healing assay. The assay was performed following a 
previously described procedure (32). In brief, the monolayer 
of cells was scraped with a 10 µl pipette tip. The migration 
of cells was photographed using a time-lapse image system 
(EVOS, Life Technologies Ltd., Paisley, UK).
Statistical analysis. Statistical analyses were performed 
using SPSS (version 11; SPSS, Inc., Chicago, IL, USA). 
Mann-Whitney U test and t-test were used for non-parametric 
and normally distributed data, respectively, including research 
data from the clinical cohort and cell-based experiments. 
Kaplan-Meier survival analysis was also performed using 
SPSS statistical software. Differences were considered to be statistically signiicant at p<0.05.
Results
Increased expression of NOV in human GC. Transcript levels 
of CYR61, CTGF and NOV were determined in the GC cohort 
using real-time PCR, respectively. The results showed that 
NOV expression was significantly upregulated in gastric 
tumours compared to normal tissue (p=0.009) (Table II). 
An increased expression of NOV in GC was associated with 
local invasion. The transcript levels of NOV were higher in 
the tumours with more advanced local invasion. According 
to the tumor-node-metastasis (TNM) staging, T4 tumours 
which invaded the serosa or adjacent structures expressed 
higher levels of NOV transcripts, p=0.0026 vs. T1. Tumours 
classified as T3 and T4 which invaded beyond subserosal 
connective tissues expressed higher levels of NOV transcripts 
in comparison with tumours (T1 and T2) with less local 
invasion (p=0.0013). According to the overall TNM staging, 
stage I GCs exhibited lower expression levels of NOV, p=0.016 
vs. stage II, p=0.0017 vs. stage III, and p=0.0007 vs. tumours 
of stage II-IV. Notably, we found that high-moderately differ-entiated tumours exhibited signiicantly lower levels of NOV 
expression in comparison with moderately and/or poorly 
differentiated tumours. However, no association was observed 
for lymph node and distant metastases.
Table I. Primers used for PCR and qPCR.
Primer Forward primer Reverse primer
NOV (PCR) CTCCAAGAAAAGTTGAGGTG CTGGCTTCTTGACTATTTGC
NOV (qPCR) CTGTGAACAAGAGCCAGAG ACTGAACCTGACCGTACACTTGAACTGCAGGTGGAT
GAPDH (PCR) GGCTGCTTTTAACTCTGGTA GACTGTGGTCATGAGTCCTT
GAPDH (qPCR) CTGAGTACGTCGTGGAGTC ACTGAACCTGACCGTACACAGAGATGACCCTTTTG
CYR61 (qPCR) GGGCTGGAATGCAACTTC ACTGAACCTGACCGTACACGTTTTGGTAGATTCTGGAG
CTGF (qPCR) GAGTGGGTGTGTGACGAG ACTGAACCTGACCGTACAGGCAGTTGGCTCTAATCATA
NOV, nephroblastoma overexpressed; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CYR61, cysteine-rich protein 61; CTGF, con-
nective tissue growth factor.
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Table III. Expression of CYR61 in gastric cancer.
Category No. Mean ± SEM (copies) P-value
Tissue
  Tumour 252 2,225±668
  Normal 175 120.1±50.5 0.0019
Gender
  Male 180 2,737±913
  Female 72 947±475 0.083
Location
  Cardia 50 3,558±2,288
  Fundus 12 322±172 0.86
  Corpus 52 2,824±1,622 0.59
  Pylorus 102 1,717±780 0.84
Differentiation
  Diff-H 1 4400.7
  Diff-HM 5 1,898±1,897
  Diff-M 52 1,890±1,426 1
  Diff-ML 64 2,537±1,747 0.81
  Diff-L 106 1,255±558 0.76
T stage
  T1 13 8,723±6,131
  T2 21 8.96±8.53 0.18
  T3 27 2,821±1,860 0.37
  T4 185 1,756±715 0.28
  T1+T2 34 3,341±2,402
  T3+T4 212 1,892±666 0.56
N stage
  N0 59 3,178±1,572
  N1 42 1,050±1,035 0.26
  N2 50 1,612±1,206 0.43
  N3 96 2,108±1,166 0.59
  N1+N2+N3 188 1,740±712 0.41
M stage
  M0 220 2,439±758
  M1 32 755±663 0.097
TNM stage
  Ⅰ 21 5,400±3,855
  Ⅱ 50 1,452±923 0.33
  Ⅲ 169 1,928±791 0.39
  Ⅳ 6 450±445 0.22
  II+Ⅲ+Ⅳ 225 1,783±628 0.36
Vascular invasion
  No invasion 124 1,739±678
  Invasion 117 2,523±1193 0.57
Clinical outcome
  Disease-free 98 2,744±1,131
  Metastases 10 418±399 0.055
  Death 142 2,026±893 0.62
CYR61, cysteine-rich protein 61; SEM, standard error of the mean; 
TNM, tumor-node-metastasis.
Table II. Expression of NOV in gastric cancer.
Category No. Mean ± SEM (copies) P-value
Tissue
  Tumour 322 8,893±1,303
  Normal 183 3,262±1,058 0.0009
Gender
  Male 230 9,583±1,645
  Female 92 7,170±1,971 0.35
Location
  Cardia 66 8,384±2,795
  Fundus 21 8,679±4,797 0.86
  Corpus 61 7,678±2,795 0.59
  Pylorus 131 8,326±1,786 0.84
Differentiation
  Diff-H 1 33,009
  Diff-HM 6 172.2±56.6
  Diff-M 62 8,677±2,779 0.0033
  Diff-ML 82 9,130±2,435 0.0004
  Diff-L 136 8,610±1,848 <0.001
T stage
  T1 16 2,754±2,450
  T2 26 4,456±2,325 0.62
  T3 41 9,478±5,181 0.25
  T4 231 9,503±1,500 0.026
  T1+T2 42 3,808±1,701
  T3+T4 272 9,499±1,490 0.013
N stage
  N0 70 8,735±2,479
  N1 48 9,123±3,036 0.92
  N2 65 5,845±3,214 0.48
  N3 133 10,311±2,106 0.63
  N1+N2+N3 246 8,899±1,538 0.96
M stage
  M0 280 8,644±1,281
  M1 41 10,813±5,350 0.7
TNM stage
  Ⅰ 25 1,847±1,569
  Ⅱ 60 9,689±2,758 0.016
  Ⅲ 219 9,261±1,672 0.0017
  Ⅳ 9 9,756±9,560 0.44
  II+Ⅲ+Ⅳ 228 9,366±1,421 0.0007
Vascular invasion
  No invasion 151 6,865±1,526
  Invasion 156 9,257±1,803 0.63
Clinical outcome
  Disease-free 119 7,464±1,832
  Metastases 15 12,921±6,376 0.42
  Death 185 9,626±1,869 0.41
NOV, nephroblastoma overexpressed; SEM, standard error of the 
mean; TNM, tumor-node-metastasis.
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CYR61 is upregulated in GCs. CYR61 mRNA levels were signiicantly elevated in the GC tissues compared to levels 
in the non-cancerous tissues (p=0.0019), particularly in 
paired tissues (p=0.0013) (Table III). However, the expres-
sion of CYR61 transcripts appeared to be lower in more 
advanced tumours (stage III and IV) according to the TNM staging, although it did not reach a statistically signiicant 
level. According to clinical outcomes, tumours with distant 
metastases had lower expression levels of CYR61 (p=0.055) 
compared with that of patients who remained disease-free. 
No association was observed between CYR61 expression and 
differentiation and local invasion.
Higher expression of CTGF in GC and the involvement in 
local invasion. Although no statistically signiicant differ-
ences were noted for CTGF mRNA levels in GCs compared 
with adjacent normal gastric tissues, a higher transcript level 
of CTGF in GCs was positively associated with local invasion (T4 vs. T1, p<0.001; T3 vs. T1, p=0.031; Table IV). However, there were no other signiicant correlations between CTGF 
mRNA levels and other clinical parameters.
Expression of CYR61, CTGF and NOV and survival of 
patients with GC. Kaplan-Meier survival curves revealed 
that GC patients with a low CYR61 transcript level had longer 
overall survival (OS) (p=0.018) and disease-free survival 
(DFS) (p=0.015) than those with a higher CYR61 transcript 
level (Fig. 1). Transcript levels of CTGF and NOV exhibited no 
correlation with either OS or DFS when individually analysed; 
however, analysis of the combination of CYR61 and CTGF 
showed that patients with lower transcript levels of these two 
genes had longer OS (p=0.033) and DFS (p=0.025). Similarly, 
analysis of combined CYR61, CTGF and NOV showed that 
patients with higher transcript levels of all three genes had a 
poorer OS (p=0.027) and DFS (p=0.021) compared to patients 
with lower expression of all these genes.
Knockdown and overexpression of NOV in GC cells. The expression proile of NOV in AGS and HGC27 cell lines was 
assessed using RT-PCR (Fig. 2A). For assessing the effect 
of NOV on cellular functions, overexpression of NOV was 
performed in the AGS cells which had an almost undetectable 
level of NOV as determined using PCR, while knockdown 
of NOV was carried out in the HGC27 cells which highly 
expressed NOV. The overexpression and knockdown of NOV 
in AGS and HGC27 transfectants were confirmed using 
RT-PCR (Fig. 2B) and western blotting (Fig. 2C).
Effect of NOV knockdown and overexpression on cell growth 
in vitro. Overexpression of NOV increased the growth of AGS cells over the periods of 3 (p<0.01) and 4 days (p<0.001) 
compared with the control cells. An opposite effect was 
observed in the HGC27 NOV-knockdown cells over the periods of 3 (p<0.01) and 4 days (p<0.01) (Fig. 3).
Effect of NOV knockdown and overexpression on the invasion, 
adhesion and migration of GC cells. Overexpression of NOV 
resulted in increased invasion in the AGS cells, while NOV 
knockdown exhibited reduced invasiveness in the HGC27 cells (p<0.001) (Fig. 4). Knockdown and overexpression of 
Table IV. Expression of CTGF in gastric cancer.
Category No. Mean ± SEM (copies) P-value
Tissue
  Tumour 320 224.3±27.9
  Normal 183 247.7±38.7 0.62
Gender
  Male 228 209.5±22.92
  Female 92 261.4±79.1 0.53
Location
  Cardia 65 251.4±54.2
  Fundus 21 234.6±66.3 0.85
  Corpus 61 158.2±44.0 0.18
  Pylorus 130 251±52.8 1
Differentiation
  Diff-H 1 16.77
  Diff-HM 6 142.2±61.4
  Diff-M 62 259.6±53.0 0.17
  Diff-ML 81 266.6±60.9 0.17
  Diff-L 135 197.6±48.1 0.49
T stage
  T1 16 49±12.2
  T2 25 218.8±93.55 0.084
  T3 41 252.3±90.0 0.031
  T4 230 231.6±33.6 0
  T1+T2 41 154.1±59.08
  T3+T4 271 234.8±31.5 0.23
N stage
  N0 70 250.7±78.5
  N1 48 120±35.1 0.13
  N2 64 292.2±57.6 0.67
  N3 132 218.7±43.3 0.72
  N1+N2+N3 244 218.9±28.9 0.7
M stage
  M0 278 199.4±26.6
  M1 41 400±119 0.11
TNM stage
  Ⅰ 25 225.8±97.01
  Ⅱ 59 197.2±83.2 0.82
  Ⅲ 218 224.5±29 0.99
  Ⅳ 9 407±349 0.63
  II+Ⅲ+Ⅳ 286 224.5±29.9 0.99
Vascular invasion
  No invasion 150 246.6±45.5
  Invasion 155 206.7±36.3 0.49
Clinical outcome
  Disease-free 119 237.3±48.9
  Metastases 15 119.2±47.6 0.09
  Death 183 227.1±36.7 0.87
CTGF, connective tissue growth factor; SEM, standard error of the 
mean; TNM, tumor-node-metastasis.
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NOV did not enhance or reduce the adhesion of the GC cells 
to Matrigel in comparison with the control cells. A wound healing assay was employed to determine the inluence of 
NOV on cell migration. There was no obvious effect observed 
in our experiments (data not shown).
Discussion
This is the irst study to assess the role played by NOV (CCN3) 
in gastric cancer (GC). In the present study, we determined 
the expression of NOV, along with CYR61 and CTGF tran-
Figure 1. Association of CYR61, CTGF and NOV expression with the survival of patients. The average expression levels for CYR61, CTGF and NOV tran-
scripts were used as thresholds. The survival of patients with higher or lower expression levels of each was analysed individually or in combination as two or 
three using the Kaplan-Meier survival analysis.
Figure 2. Knockdown and overexpression of NOV in GC cell lines. (A) The expression of NOV in the AGS and HGC27 cell lines using RT-PCR. (B) Overexpression of NOV in the AGS cell line and knockdown of NOV in the HGC27 cell line were veriied using RT-PCR. (C) Veriication of the knockdown and overexpres-sion was further conirmed using western blotting.
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scripts in a cohort of human GCs and paired adjacent normal 
gastric tissues. Increased expression of NOV was observed 
in the GC tissues compared with the expression noted in the 
adjacent normal gastric tissues. Increased expression was 
found to be associated with local invasion and poorer differen-
tiation. Elevated expression of NOV in GC is consistent with 
observations in other cancers. For example, overexpression of 
NOV is evident in prostate cancer and cervical cancer and is 
involved in tumourigenesis and disease progression (19,20). 
Overexpression of NOV in cervical cancers was found to be 
associated with lymph node metastases and poorer prognosis 
of cervical cancer patients (20). This suggests that NOV is posi-
tively involved in tumourigenesis and disease progression by 
regulating morphological transformation and the invasiveness 
of GC cells. Our previous study showed reduced expression of 
NOV in breast cancer which was associated with poor prog-
nosis and mortality of the disease (15). Differential expression 
patterns and roles can be played by NOV in different malig-nancies which can be organ- or tissue-speciic.
In the present study, we also determined the transcript 
levels of CYR61 and CTGF in GC samples. Similarly, over-
expression of CYR61 transcripts was noted in GC although 
no difference was observed for the expression of CTGF. No 
association was clearly evident for elevated expression of 
CYR61 and disease progression in the present cohort of GC 
cases. Overexpression of CYR61 has been observed in many 
different cancers, including prostate, breast, ovarian, endome-
trial and colorectal carcinomas (11,12,33-35). In contrast to the 
elevated expression of CYR61 in these malignancies, reduced 
expression has also been noted in various types of cancers, in 
particular GC which is associated with local invasion (23). In 
the present study, a trend of reduced expression of CYR61 was 
also noted in the more advanced GCs appearing to be in line 
with observations made by Maeta et al (23). A controversy may 
Figure 3. Inluence of altered NOV expression on in vitro proliferation of the GC cell lines. The proliferation of (A) AGS and (B) HGC27 cells with knockdown 
or overexpression of NOV was determined using an in vitro growth assay over a culture period of up to 4 days. Three independent experiments were performed. 
Shown are representative results from these experiments and the error bars show standard deviations; **p<0.01 and ***p<0.001.
Figure 4. Effect of the altered expression of NOV on the invasiveness of GC cells.
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still exist for its role in GC as experimental evidence using GC 
cell lines indicates that CYR61 can promote invasion, metas-
tasis and angiogenesis in GC (29-31). The present study also 
showed a link between higher CYR61 expression and poorer survival outcomes of patients with GC. This was also relected 
in the survival analysis of the combined expression of CYR61 
with CTGF, or CTGF and NOV (Fig. 1). CTGF and NOV alone 
or combined did not exhibit any correlation with survival (data 
not shown). This suggests that a more profound role is played 
by CYR61 in GC which is also supported by studies of this 
molecule in GC (30,36). In a comparison with NOV expression 
and corresponding association between elevated NOV expres-
sion and local invasion and poorer differentiation of GCs, the 
increased expression CYR61 exhibited little implication with 
these clinicopathological features of the disease apart from 
its correlation with poor prognosis. A larger cohort of GC 
tissue samples may help to clarify this. Better understanding 
of the molecular mechanisms of GC may shed light on this 
issue in the near future.
Although the expression of CTGF transcripts in the 
present cohort of GCs was not different from its expression 
in the paired adjacent normal gastric tissues, its expres-
sion was increased in more invasive tumours. This tends to 
concur with observations from other studies focusing on this 
molecule and its role in GC. Higher expression of CTGF in 
GC exhibits involvement in local lymph node metastasis 
and also peritoneal metastasis (37,38). Suppression of CTGF 
inhibits the growth and invasion of GC cells, and also their 
peritoneal dissemination (39). In addition to its role in invasion 
and metastases, CTGF also promotes angiogenesis to facilitate 
tumour growth (40).
In addition to the evaluation of NOV, CYR61 and CTGF 
transcripts in the GC samples, we further examined the impact 
of NOV on cellular functions in GC cell lines. The two GC 
cell lines examined in the present study exhibited differential 
expression of NOV, where NOV was highly expressed in the 
HGC27 cells and almost absent in the AGS cells. This allowed 
us to establish contrasting models, i.e. overexpression of NOV 
in AGS cells and knockdown of NOV expression in HGC27 
cells, for examining the consequent effect on the cellular func-
tions. NOV overexpression promoted the in vitro proliferation 
of AGS cells while the knockdown resulted in reduced prolif-
eration of the HGC27 cells. A similar effect was observed in 
regards to the invasion of these two GC cell lines. These results 
indicate a positive role played by NOV in promoting prolifera-
tion and invasion of GC which is consistent with its increased 
expression in the GC tumour samples. Increased expression 
of NOV has also been observed in other malignancies, such 
as cervical and prostate cancer (19,20). Certainly, an inhibi-
tory effect on cellular functions has also been noted for NOV 
in a variety of cancer cells. For example, NOV had an anti-
proliferative effect on glioblastoma cells by interfering with S/
G2 transition of the cell cycle leading to an accumulation at the 
S phase (25). Gap junction protein connexin 43 was also found 
to be involved in its inhibitory effect on the proliferation of 
glioma cells (41). NOV has also been reported to decrease the 
transcription and activation of matrix metalloproteinases and 
suppress the invasion of melanoma cells (42). However, our 
in vitro experimental data indicate that NOV promotes both 
proliferation and invasion of GC cells. Further investigation 
may shed light on the underlying molecular mechanisms for 
such a differential impact.
In summary, the expression of NOV and CYR61 was 
increased in GC. The elevated expression of CYR61 was 
associated with poorer survival, and NOV promoted the prolif-
eration and invasion of GC cells.
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